Comparisons

Retatrutide vs Tirzepatide: What's the Difference and Which Is Right for You?

If you've been researching weight loss medications, you've likely heard about Tirzepatide—the dual-action GLP-1 medication that's been making headlines for its impressive results. But there's a newer medication generating even more buzz: Retatrutide. Both are injectable medications designed to help with weight loss and metabolic health, but they work in distinctly different ways. Understanding these differences can help you have a more informed conversation with your healthcare provider about which option might be right for your journey.

What Is Tirzepatide?

Tirzepatide is a dual-action medication that activates two hormone receptors in your body: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It's FDA-approved for type 2 diabetes under the brand name Mounjaro and for weight management under the brand name Zepbound.

This medication works by helping you feel fuller longer, slowing how quickly food leaves your stomach, and improving how your body responds to insulin. In clinical trials, people taking Tirzepatide lost an average of 15-22% of their body weight over 72 weeks—results that have genuinely changed the conversation around medical weight management.

Tirzepatide is administered as a once-weekly injection, starting at a low dose and gradually increasing to minimize side effects while maximizing results.

What Is Retatrutide?

Retatrutide is a newer medication that takes a triple-action approach. It activates three hormone receptors: GLP-1, GIP, and glucagon. As of early 2025, Retatrutide is still in Phase 3 clinical trials and has not yet received FDA approval, though the results so far have been remarkable.

The addition of glucagon receptor activation sets Retatrutide apart. Glucagon plays a role in how your body burns energy and metabolizes fat. By targeting this third pathway in addition to appetite and blood sugar regulation, Retatrutide may offer even more significant weight loss results than current medications.

Early clinical trial data showed participants losing an average of 24% of their body weight at 48 weeks—potentially making it one of the most effective weight loss medications studied to date.

How They Work Differently in Your Body

While both medications affect GLP-1 and GIP receptors, the key difference lies in Retatrutide's additional glucagon receptor activation.

The Dual-Action Approach of Tirzepatide

Tirzepatide's two-pronged mechanism focuses on:

The Triple-Action Approach of Retatrutide

Retatrutide does everything Tirzepatide does, but adds:

Think of it this way: Tirzepatide helps you eat less and process food more efficiently. Retatrutide does that too, but also helps your body burn more energy throughout the day.

Comparing Weight Loss Results

The numbers from clinical trials are striking, though it's important to remember that individual results vary significantly.

Tirzepatide has demonstrated consistent, substantial weight loss in FDA-approved studies. At the highest dose (15 mg), participants in the SURMOUNT-1 trial lost an average of 22.5% of their body weight over 72 weeks. That's transformative for many people who have struggled with weight for years.

Retatrutide's Phase 2 trial results showed even greater weight loss—up to 24% at 48 weeks at the 12 mg dose. However, these are earlier-stage trials with fewer participants, and we're still waiting for the larger Phase 3 studies to confirm these results across diverse populations.

It's worth noting that both medications showed that weight loss continued throughout the study periods, suggesting that longer treatment might lead to even better outcomes.

Side Effects and Tolerability

Both medications share similar side effect profiles, which makes sense given their overlapping mechanisms. The most common side effects include:

Most side effects are mild to moderate and improve as your body adjusts to the medication. Starting at a low dose and increasing gradually helps minimize these effects.

Because Retatrutide is still in trials, we have less long-term safety data compared to Tirzepatide. The glucagon component may theoretically affect heart rate or cause different metabolic effects, but so far, the safety profile appears similar to Tirzepatide.

Gender Differences to Consider

Clinical trials for both medications included both men and women, and both genders experienced significant weight loss. However, there are some patterns worth noting.

Women may experience more nausea initially, particularly in the week before menstruation when hormonal fluctuations can amplify gastrointestinal sensitivity. Some women find that timing dose increases to avoid the premenstrual week helps with tolerability.

Men typically have higher baseline metabolic rates and may see slightly faster initial weight loss, though women often achieve comparable or even greater percentage weight loss over the full treatment period.

For women in perimenopause or menopause, both medications may be particularly helpful, as this life stage often brings metabolic changes that make weight management more challenging. The metabolic benefits extend beyond weight loss to improvements in insulin sensitivity and inflammation.

Availability and Cost Considerations

This is where the practical differences become important.

Tirzepatide is FDA-approved and available now through prescription. You can get the brand-name versions (Mounjaro or Zepbound) or compounded versions through telehealth providers. Insurance coverage varies, and out-of-pocket costs can range significantly depending on your source and whether you use a compounded version.

Retatrutide is not yet available outside of clinical trials. If the Phase 3 trials continue to show positive results, it might receive FDA approval sometime in 2026 or 2027, but that timeline isn't guaranteed. Once approved, it will likely be expensive initially, similar to how other new weight loss medications launch.

Which Medication Might Be Right for You?

Right now, Tirzepatide is the only option between the two that you can actually access through your healthcare provider. It has a proven track record, FDA approval, and substantial clinical evidence supporting both its effectiveness and safety.

Retatrutide is promising and may offer even better results, but it's not yet available for prescription use. If you're interested in it, you might consider enrolling in a clinical trial if you qualify, or waiting until it receives FDA approval.

The best medication for you depends on multiple factors: your medical history, weight loss goals, other health conditions, budget, and how you respond to treatment. This is a decision to make with a qualified healthcare provider who knows your complete health picture.

From the Ozari Care Team

While Retatrutide shows exciting promise for the future, Tirzepatide remains a highly effective option available today that's changing lives. If you're experiencing side effects on any GLP-1 medication, don't suffer in silence—often simple adjustments like taking it at a different time of day, eating smaller meals, or temporarily pausing dose increases can make a significant difference in your comfort while still achieving your goals.

At Ozari Health we offer compounded Semaglutide and Tirzepatide starting at $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically reviewed by the Ozari Clinical Care Team, licensed physicians specializing in metabolic health and GLP-1 therapy. Last reviewed: April 29, 2026